PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (PTCT) was upgraded by Raymond James Financial, Inc. to "moderate buy".
PTC Therapeutics (PTCT) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $108.00 price target on the stock.
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty [Yahoo! Finance]
PTC Therapeutics (PTCT) had its "hold" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $76.00 price target on the stock, down from $91.00.